Details of the Drug
General Information of Drug (ID: DMYBNCO)
Drug Name |
7-bromo-1H-indazole
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
7-bromo-1H-indazole; 53857-58-2; 7-Bromoindazole; 7-Bromo-2H-indazole; 845751-59-9; 1H-Indazole, 7-bromo-; 1H-INDAZOLE,7-BROMO-; CHEMBL439566; AK-26850; PubChem14406; 2H-Indazole, 7-bromo-; ACMC-1B1ZL; BROMOINDAZOLE(7-); T56 BMNJ IE; KSC268A6L; 7-Bromo-1H-indazole, 97%; SCHEMBL1855857; CTK1G8065; MolPort-027-946-828; MolPort-006-717-407; KMHHWCPTROQUFM-UHFFFAOYSA-N; ZX-AT005164; BCP00108; STL555654; 2999AC; FCH835100; ANW-31868; ZINC14007945; MFCD07371564; BBL101857; SBB092096; BDBM50209239; AKOS016013628; AKOS005072291; RTC-062730; RP04094
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 197.03 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||